// App-Quantinova.ai

342 : Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.

Researchers

Presenter

  • Stefania Eufemia Lutrino

Principal Investigators

  • Orazio Caffo

  • Francesco Massari

  • Francesco Atzori

  • Claudia Maggi

  • Nicola Calvani

  • Cosimo Sacco

  • Antonello Veccia

  • Alessandra Modena

  • Silvia Cugudda

  • Elena Verzoni

  • Chiara Caliolo

  • Paola Ermacora

  • Francesca Maines

  • Giampaolo Tortora

  • Giuseppe Procopio

  • Pasqualinda Ferrara

  • Gianpiero Fasola

  • Saverio Cinieri

Medical Centers

  • Perrino Hospital, Brindisi, Italy

  • University Hospital, Udine, Italy

  • Santa Chiara Hospital, Trento, Italy

  • Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy

  • Struttura Complessa di Oncologia Medica, A.O.U. di Cagliari, Cagliari, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Oncology Department A Perrino Hospital, Brindisi, Italy

  • Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

  • Department of Medical Oncology, Hospital-University, Cagliari, Italy

  • Medical Oncology & Breast Unit, Brindisi, Italy

  • University Hospital S. Maria della Misericordia, Udine, Italy

  • Sen Antonio Perrino Hospital, Francavilla Fontana, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

  • Endocrine/metabolic Diseases (ME)

Disease

  • Metastatic castration-resistant prostate cancer

  • Obesity

  • Solid malignancies

Biomarkers

  • Body mass index

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved